-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Tenecteplase (TNK) is a novel and improved tissue plasminogen activator (tPA)
.
It has many advantages over alteplase, including longer half-life, higher fibrin specificity, and lower fibrinogen depletion potential
It has many advantages over alteplase, including longer half-life, higher fibrin specificity, and lower fibrinogen depletion potential
Thrombosis due to ease of administration—a single bolus of alteplase rather than a 1-hour infusion following the bolus—is especially beneficial in the setting of patient transfers between hospitals
Blood vessel
We performed a pooled analysis of the EXTEND-IA TNK randomized controlled trials (n = 502)
.
Patients were adults with ischemic stroke due to intracranial carotid, middle cerebral, or basilar artery occlusion presenting within 4.
RESULTS: Among patients older than 80 years (n = 137), TNK 0.
25 mg/kg versus 0.
40 mg/kg resulted in improved 90-day mRS (median 3 vs 4, acOR=2.
70, 95% CI 1.
23 -5.
94) and decreased mortality (acOR=0.
34, 95% CI 0.
13-0.
91)
.
TNK 0.
In patients older than 80 years (n = 137), TNK 0.
No differences in 90-day mRS or mortality were found between alteplase and TNK 0.
40 mg/kg
.
Symptomatic ICH occurred in 4 patients receiving TNK 0.
No differences in 90-day mRS or mortality were found between alteplase and TNK 0.
In conclusion, TNK 0.
references:
Safety and Efficacy of Tenecteplase in Older Patients With Large Vessel Occlusion A Pooled Analysis of the EXTEND-IA TNK Trials.
Safety and Efficacy of Tenecteplase in Older Patients With Large Vessel Occlusion A Pooled Analysis of the EXTEND-IA TNK Trials.
Leave a Comment
